|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|4.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
|5.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|1.||Pui, Ching-Hon: 81 articles (10/2015 - 01/2002)|
|2.||Pieters, Rob: 67 articles (12/2015 - 02/2003)|
|3.||Relling, Mary V: 60 articles (10/2015 - 01/2002)|
|4.||Kantarjian, Hagop: 60 articles (07/2015 - 03/2002)|
|5.||Schrappe, Martin: 55 articles (11/2015 - 06/2002)|
|6.||O'Brien, Susan: 55 articles (06/2015 - 01/2002)|
|7.||Evans, William E: 51 articles (10/2015 - 01/2002)|
|8.||Cortes, Jorge: 44 articles (07/2015 - 03/2002)|
|9.||Pieters, R: 42 articles (06/2015 - 08/2000)|
|10.||Hunger, Stephen P: 41 articles (10/2015 - 05/2004)|
|1.||Methotrexate (Mexate)FDA LinkGeneric
02/01/2001 - "Methotrexate (MTX) is a key drug in the curative regimen of children with acute lymphocytic leukemia. "
05/01/1997 - "Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?"
04/01/2005 - "We reported that children with B-progenitor-cell acute lymphoblastic leukemia (BpALL) treated in the early 1980s whose lymphoblasts accumulated high levels of methotrexate (MTX) and of methotrexate polyglutamates (MTXPGs) in vitro had an improved 5-year event-free survival (EFS) (65% (standard error (s.e.) 12%) vs 22% (s.e. "
11/01/2002 - "The addition of methotrexate to treatment protocols in children with acute lymphoblastic leukemia has been found beneficial in preventing central nervous system relapse. "
09/01/1998 - "Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia."
|2.||imatinib (Gleevec)FDA Link
09/01/2005 - "Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission."
10/01/2004 - "Using quantitative reverse-transcription polymerase chain reaction we investigated the significance of achieving molecular complete remission (CR) in 12 patients with bcr/abl-positive acute lymphocytic leukemia treated with imatinib. "
10/01/2004 - "The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients."
10/01/2003 - "Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission."
11/01/2005 - "In addition, imatinib is much less effective in advanced phase-CML as well as in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL), mainly due to the development of drug resistance. "
|3.||Asparaginase (Elspar)FDA Link
12/01/2008 - "The outcome of pediatric acute lymphoblastic leukemia (ALL) has improved dramatically over the last 40 years through a systematic approach of well-designed large trials including use of asparaginase. "
06/01/2012 - "The use of L-asparaginase (ASNase) to modify amino acid metabolism is one of the most effective chemotherapeutic means of inducing remission in acute lymphoblastic leukemia (ALL). "
02/01/2008 - "L-asparaginase (ASNase) is one of the most effective chemotherapeutic means for inducing remission in acute lymphoblastic leukemia. "
03/27/2014 - "This study prospectively analyzed the efficacy of very prolonged courses of pegylated Escherichia coli asparaginase (PEGasparaginase) and Erwinia asparaginase in pediatric acute lymphoblastic leukemia (ALL) patients. "
05/01/1987 - "We studied platelet function and plasma coagulation parameters in 12 pediatric patients with acute lymphoblastic leukemia (ALL) receiving daily L-asparaginase as a single agent when in complete remission. "
|4.||Cytarabine (Cytosar-U)FDA LinkGeneric
12/01/2001 - "Cytosine arabinoside has been less well studied in relation to childhood ALL, although evidence exists to suggest that the administration of conventional-dose bolus or infusion schedules may not be optimal in terms of the antileukaemic efficacy of this antimetabolite. "
12/01/1998 - "Our results show the efficacy of the intermediate dose ARA-C plus IDA schedule for high risk adult and childhood ALL patients. "
09/15/1987 - "Low-dose cytosine arabinoside-induced remission of lymphoblastic leukemia in a cat."
10/04/1980 - "Whereas in the 1960s only 4/19 achieved (short) remission, now, since the introduction of cytosine arabinoside, remissions are observed on 79% but median survival (10 months) is still short compared with acute lymphocytic leukemia. "
06/01/2015 - "Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia."
|5.||Vincristine (Oncovin)FDA LinkGeneric
04/01/1990 - "An 11 year-old girl was diagnosed as acute lymphoblastic leukemia (ALL) on November 26th 1979 and was induced into complete remission with vincristine and prednisolon. "
02/01/2008 - "The microtubule-depolymerizing drug, vincristine, is effective in the treatment of acute lymphoblastic leukemia (ALL). "
01/01/1982 - "One child with acute lymphocytic leukemia resistant to vincristine had a transient M1 remission bone marrow. "
02/24/2015 - "Genome-wide association study of patients in 1 of 2 prospective clinical trials for childhood ALL that included treatment with 36 to 39 doses of vincristine. "
09/01/2006 - "Trial initiated for liposomal vincristine in relapsed/refractory acute lymphoblastic leukemia."
|6.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
03/01/2000 - "The current approach of allogeneic BMT from an unrelated donor when no sibling donor is available, following conditioning with cyclophosphamide/ fractionated TBI has resulted in a reduced relapse rate and improved short-term overall survival in the treatment of relapsed childhood ALL. "
02/16/1963 - "[Trial treatment by cyclophosphamide of acute lymphoblastic leukemia and lymphoblastosarcoma]."
07/01/2014 - "High-dose cyclophosphamide for the treatment of refractory T-cell acute lymphoblastic leukemia in children."
03/01/1981 - "Cyclophosphamide was administered to 42 patients with acute lymphocytic leukemia (ALL) as a daily continuous iv infusion at a dose of 400 mg/m2/day x 5 days; the courses of treatment were repeated every 3 weeks. "
02/01/1977 - "Children with B-lymphoblastic lymphoma usually benefit from cyclophosphamide therapy; the value of irradiation is yet to be established. "
|7.||Prednisone (Sone)FDA LinkGeneric
09/01/2011 - "GIMEMA ALL 0288 trial was designed to evaluate the impact of a 7-day prednisone (PDN) pretreatment on complete remission of acute lymphoblastic leukemia. "
12/01/2010 - "NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols."
05/01/2013 - "In the ALL-BFM studies for treatment of acute lymphoblastic leukemia, reduction of leukemic blasts in peripheral blood after a one-week prednisone pre-phase - the so-called prednisone response - has been used for risk stratification since the 1980s and has been one of the most relevant factors for identification of high-risk patients. "
07/01/2012 - "In the ALL-BFM 95 trial for treatment of acute lymphoblastic leukemia, response to a prednisone pre-phase (prednisone response) was used for risk stratification in combination with age and white blood cell count at diagnosis, response to induction therapy and specific genetic high-risk features. "
01/01/2011 - "This study aimed to assess changes in NF-ĸB activation in peripheral blood mononuclear cells prior to and after 6 and 12 h of prednisone administration in relation to age, initial WBC count at diagnosis and early treatment response in childhood ALL. "
|8.||6-Mercaptopurine (Mercaptopurine)FDA LinkGeneric
01/01/2000 - "6-mercaptopurine (6-MP) has been used clinically for 40 years to maintain remission in patients with acute lymphoblastic leukemia (ALL). "
01/01/1991 - "To evaluate the reasons for the wide variability in bioavailability of orally administered 6-mercaptopurine in children with acute lymphoblastic leukemia, we studied several pharmacokinetic parameters of the drug in 18 affected children receiving remission maintenance therapy, and compared them with their anthropometric data and with the results of intestinal function tests. "
11/01/1989 - "Plasma levels of 6-mercaptopurine were determined in 22 consecutive children with acute lymphoblastic leukemia on oral remission maintenance therapy during the time period of August 1984 to January 1988. "
01/01/1988 - "In three children receiving oral remission maintenance therapy for acute lymphoblastic leukemia, the concentrations of 6-mercaptopurine (6-MP) in cerebrospinal fluid (CSF), plasma and red blood cells were compared. "
08/01/2004 - "A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group)."
|9.||Doxorubicin (Adriamycin)FDA LinkGeneric
06/01/2015 - "CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia."
01/01/1981 - "Low-dose adriamycin remission maintenance for advanced acute lymphoblastic leukemia: a Southwest Oncology, Group study."
03/21/1991 - "We therefore assessed the cardiac status of 115 children who had been treated for acute lymphoblastic leukemia with doxorubicin 1 to 15 years earlier in whom the disease was in continuous remission. "
06/01/1988 - "Improved treatment results for lymphoblastic lymphoma in adolescents and adults using a doxorubicin-based (APO) protocol."
07/01/2015 - "In this study, we investigated the molecular mechanism of doxorubicin (dxr)-induced cytotoxicity on Jurkat cells - a model cell of human acute lymphoblastic leukemia - under normoxic (20% O2) and hypoxic (5% O2) conditions. "
|10.||dasatinib (BMS 354825)FDA Link
08/01/2012 - "Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification."
03/01/2009 - "Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia."
09/01/2012 - "In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia."
08/01/2012 - "H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia."
01/01/2012 - "Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation."
|1.||Drug Therapy (Chemotherapy)
01/01/2005 - "The aim of our study was to find which progenitor cells are most suitable for the preparation of dendritic cells in acute lymphoblastic leukemia (ALL) in pediatric patients, whether blasts from bone marrow or dendritic cells generated from peripheral blood mononuclear cells taken at the time of remission after induction chemotherapy. "
05/01/1997 - "Studies in the last decade show that most adults with acute lymphocytic leukemia (ALL) can achieve remission with intensive induction chemotherapy. "
09/01/2012 - "Risk-adapted intensive chemotherapy is effective in treating most children with B-acute lymphoblastic leukemia, but this approach is less successful in adults. "
06/01/2012 - "Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. "
01/01/2002 - "It is concluded that good results in childhood ALL treatment can be achieved without resorting to high-dosage chemotherapy and radiation in most cases."
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
12/01/1993 - "In a retrospective multicentre study, we analyzed 184 consecutive patients who underwent bone marrow transplantation (BMT) from identical siblings for adult acute lymphoblastic leukemia in first complete remission between March 1980 and May 1989. "
09/01/2009 - "Continued complete remission without systemic therapy for isolated testicular relapse after bone marrow transplantation in a boy with acute lymphoblastic leukemia."
10/01/2006 - "A 42-year-old woman was referred to us for the treatment of relapsed Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), which had been maintained in complete remission for seven years after an allogeneic bone marrow transplantation (allo-BMT) from an unrelated donor. "
07/01/2005 - "Donor leukocyte infusion (DLI) alone has very limited efficacy for patients with acute lymphoblastic leukemia (ALL) who have relapsed after allogeneic bone marrow transplantation (BMT). "
02/01/2004 - "The role of allogeneic bone marrow transplantation (alloBMT) in adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) remains controversial. "
10/01/1989 - "Among the former, the most common condition is acute lymphoblastic leukemia, in which a bone marrow transplant can be performed during the second or first complete remission (CR). "
12/01/2013 - "Current salvage regimens achieve complete remission (CR) in about a third of adults with relapsed/refractory acute lymphoblastic leukemia (ALL), and this represents a major barrier for performing allogeneic hematopoietic stem cell transplant (HSCT), the only potentially curative treatment. "
09/01/2009 - "Transplant decisions for children with acute lymphoblastic leukemia (ALL) in second complete remission (CR2) are often based on the type of available donor. "
07/15/2008 - "We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004. "
07/15/2008 - "Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission."
|4.||Transplantation (Transplant Recipients)
10/08/1981 - "This study demonstrates that marrow transplantation currently offers the best chance of long-term remission and potential cure after a child with acute lymphoblastic leukemia has had a relapse in the marrow."
06/20/2007 - "Transplantation in childhood very high risk acute lymphoblastic leukemia in first complete remission: where are we now?"
09/01/2002 - "An 11-month-old boy with acute lymphoblastic leukemia (ALL) underwent umbilical cord blood transplantation (CBT) from an unrelated donor after a first complete remission. "
03/01/1990 - "Allogenic versus autologous marrow transplantation for patients with acute non lymphoblastic leukemia in first complete remission."
09/01/2004 - "This approach offers a promising treatment option for patients with acute lymphoblastic leukemia needing urgently transplantation but lacking a suitable donor."
|5.||Stem Cell Transplantation
10/01/1998 - "The best post-remission therapy for patients with acute lymphoblastic leukemia (ALL) is controversial, and hemopoietic stem cell transplantation (HSCT) is one therapeutic option. "
02/01/2006 - "To evaluate the results of autologous stem cell transplantation (ASCT) in a large population of adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR), we performed an individual data-based overview of the last three trials from the LALA group. "
02/01/2006 - "Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials."
08/01/2013 - "Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission."
09/01/2004 - "We performed HLA-mismatched stem cell transplantations with megadoses of purified positively selected mobilized peripheral blood CD34+ progenitor cells (PBPC) from adult donors in 27 children with acute lymphoblastic leukemia (ALL) in first (CR1 n = 7), second (CR2 n = 10), or third (CR3 n = 4) complete remission, and in refractory state (NR n = 6). "